Skip to main content
. 2023 Sep 12;15(18):4522. doi: 10.3390/cancers15184522

Table 2.

Ongoing clinical trials with T-DXd including metastatic BC patients.

NCT Identifier Trial Name Phase Experimental Arm Control Arm Setting Primary Endpoint
NCT04538742 DESTINY-Breast 07 I/II
  • -

    T-DXd.

  • -

    T-DXd plus durvalumab.

  • -

    T-DXd plus pertuzumab.

  • -

    T-DXd plus paclitaxel.

  • -

    T-DXd plus durvalumab plus paclitaxel.

  • -

    T-DXd plus Tucatinib.

 - ≥2nd line AEs
NCT04556773 DESTINY-Breast 08 I
  • -

    T-DXd plus capecitabine.

  • -

    T-DXd plus durvalumab plus paclitaxel.

  • -

    T-DXd plus capivasertib.

  • -

    T-DXd plus anastrozole.

  • -

    T-DXd plus fulvestrant tucatinib.

 - ≥2nd line AEs
NCT04494425 DESTINY-Breast 06 III
  • -

    T-DXd

 Investigator’s choice standard of care chemotherapy (capecitabine, paclitaxel, nab-paclitaxel) 1st line PFS
NCT04829604 ACE-Breast 03 II
  • -

    ARX788

 - ORR
NCT04784715 DESTINY-Breast 09 III
  • -

    T-DXd plus pertuzumab-matching placebo.

  • -

    T-DXd plus pertuzumab.

 Investigator’s choice standard of care (Taxane (paclitaxel or docetaxel), trastuzumab, and pertuzumab) 1st line PFS
NCT05744375 TRASCENDER study II
  • -

    T-DXd

 - 2nd line (early relapse) ORR
NCT04752059 T-DXd; DS-8201a II
  • -

    T-DXd

 - ORR brain met
NCT04539938 HER2CLIMB-04 II
  • -

    Tucatinib plus T-DXd

 - ORR
NCT04739761 DESTINY-Breast 12 III
  • -

    T-DXd

 - No more than 2 lines ORR

AEs: Adverse events. PFS: Progression-free survival. ORR: Objective response rate.